HighGravityDataHumana — Apr 30, 2025 release
Fiscal 2025 first-quarter results · 8-K Item 2.02 · Exhibit 99.1 · 0000049071-25-000021
Showing in the filing
Insurance segment benefit ratio
“90.1 percent to 90.5 percent”
Period
FY2025
Measure
Company-defined measure
Source
Prose
All guidance in this release · 22
GAAP EPS for FY2025
“approximately $14.68”
Insurance segment benefit ratio for FY2025
“90.1 percent to 90.5 percent”
Adjusted FY 2025 EPS for FY2025
“approximately $16.25”
Diluted earnings per share (EPS) - Adjusted … for FY2025
“approximately $16.25”
Diluted earnings per common share (EPS) GAAP for FY2025
“approximately $14.68 (previously approximately $15.88)”
Diluted earnings per share (EPS) - GAAP for FY2025
“approximately $14.68”
Total Revenues Consolidated - GAAP for FY2025
“$126 billion to $128 billion”
Total Revenues Insurance segment - GAAP for FY2025
“$121 billion to $123 billion”
Total Revenues CenterWell segment - GAAP for FY2025
“$20.5 billion to $21.5 billion”
Change in year-end medical membership - Indi… for FY2025
“Decline of approximately 550,000”
Individual Medicare Advantage annual members… for FY2025
“approximately 550,000”
Change in year-end medical membership - Grou… for FY2025
“Relatively flat”
Change in year-end medical membership - Medi… for FY2025
“Growth of approximately 200,000”
Change in year-end medical membership - Stat… for FY2025
“Growth within 175,000 to 250,000 range”
Operating Cost Ratio - Consolidated GAAP for FY2025
“11.3% to 11.7%”
Segment Results - Insurance segment income f… for FY2025
“$1.5 billion to $2.0 billion”
CenterWell segment income from operations - … for FY2025
“$1.0 billion to $1.5 billion”
CenterWell segment income from operations - … for FY2025
“$1.2 billion to $1.7 billion”
Effective Tax Rate - GAAP for FY2025
“approximately 25.0%”
Weighted Avg. Share Count for Diluted EPS for FY2025
“approximately 121.5 million”
Cash flows from operations - GAAP for FY2025
“$2.4 billion to $2.9 billion”
Capital expenditures for FY2025
“approximately $650 million”
Exhibit 99.1 · the passage around this item
… earlier in the release
Box 1438 Louisville, KY 40202 http://www.humana.com FOR MORE INFORMATION CONTACT: Lisa Stoner Humana Investor Relations (502) 580-2652 e-mail: LStamper@humana.com Mark Taylor Humana Corporate Communications (317) 753-0345 e-mail: MTaylor108@humana.com Humana Reports First Quarter 2025 Financial Results; Affirms Full Year 2025 Adjusted Financial Guidance • Reports 1Q25 earnings per share (EPS) of $10.30 on a GAAP basis, Adjusted EPS of $11.58 • 1Q25 Insurance segment benefit ratio of 87.4 percent, in line with the company's previously disclosed expectation of 'approximately 87.5 percent' • Affirms Adjusted FY 2025 EPS guidance of 'approximately $16.25'; while revising GAAP EPS to 'approximately $14.68' from the previous estimate of 'approximately $15.88' • Affirms FY 2025 Insurance segment benefit ratio guidance range of 90.1 percent to 90.5 percent • Affirms expected individual Medicare Advantage annual membership decline of approximately 550,000, inclusive of the impact of exiting certain unprofitable plans and counties ◦ Remains confident in 2025 pricing strategy as the company prioritizes membership that is expected to drive sustainable, long-term value creation • Continues to advance the company's long-term strategy with achievements within the CenterWell and Medicaid businesses ◦ CenterWell Pharmacy selected as the fulfillment pharmacy for NovoCare ® Pharmacy’s weight loss medication for cash pay customers ◦ Illinois announced its intent to award the company a contract for the state's new Fully Integrated Dual Eligible Special Needs Plan program • Publishes prepared management remarks to Investor Relations page of www.humana.com ahead of this morning's 8:00 a.m. ET question and answer session to discuss its financial results for the quarter and expectations for future earnings LOUISVILLE, KY (April 30, 2025) – Humana Inc. (NYSE: HUM) today reported consolidated pretax results and net earnings per share (EPS) for the quarter ended March 31, 2025 (1Q25) versus the quarter ended March 31, 2024 (1Q24) as noted in the tables
later in the release …
the item shown at left
other guidance in this release
Text is the filed exhibit, verbatim.